Tech Company Financing Transactions
Cellares Funding Round
Cellares secured a $255 million Series C financing round on 8/23/2023. Investors included Koch Disruptive Technologies, 8VC and Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
8/23/2023
Transaction Type
Venture Equity
Amount
$255,000,000
Round
Series C
Investors
Koch Disruptive Technologies (Lead Investor) (David Mauney)
Proceeds Purpose
The company intends to use the funds to launch a commercial-scale IDMO Smart Factory, which integrates advanced robotics, purpose-built technology, and interconnected software.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
345 Allerton Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Cellares is working to make cell therapy widely available and affordable by providing preclinical and clinical scientists as well as commercial cell therapy manufacturers with a flexible and scalable manufacturing solution and fully-integrated software.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fabian Gerlinghaus
Chief Technical Officer
Alex Pesch
President
Omar Kurdi
Browse more venture capital transactions:
Prev: 8/23/2023: Schuttflix venture capital transaction
Next: 8/23/2023: Lumina DEX venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs